Delaware Healthcare’s attractive, ordinary, and unappealing features continue to offset each other, and it remains a middling source of exposure to its target sector.
Delaware Healthcare I DLHIX
- NAV / 1-Day Return 27.28 / +1.11 %
- Total Assets 771.6 Mil
-
Adj. Expense Ratio
- Expense Ratio 0.960%
- Distribution Fee Level Above Average
- Share Class Type Institutional
- Category Health
- Investment Style Large Blend
- Min. Initial Investment —
- Status Open
- TTM Yield 0.78%
- Turnover 3%
USD | NAV as of May 03, 2024 | 1-Day Return as of May 03, 2024, 11:42 PM GMT+0
Morningstar’s Analysis DLHIX
Will DLHIX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 52.5
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 11.80 | 93.4 Mil | Healthcare |
Amgen Inc | 7.08 | 56.0 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 6.20 | 49.1 Mil | Healthcare |
Merck & Co Inc | 4.92 | 38.9 Mil | Healthcare |
UnitedHealth Group Inc | 4.75 | 37.6 Mil | Healthcare |
Elevance Health Inc | 4.13 | 32.7 Mil | Healthcare |
Pfizer Inc | 3.91 | 30.9 Mil | Healthcare |
Viking Therapeutics Inc | 3.42 | 27.1 Mil | Healthcare |
Boston Scientific Corp | 3.29 | 26.0 Mil | Healthcare |
AbbVie Inc | 2.99 | 23.7 Mil | Healthcare |